DICERNA PHARMACEUTICALS, INC.

(DRNA)
Delayed Nasdaq  -  12/27 04:00:00 pm EST
38.22 USD   +0.58%
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisition
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQGS : DRNA) dropped from S&P Global BMI Index
CI
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Global BMI Index

12/30/2021 | 12:00am EDT

Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Global BMI Index


© S&P Capital IQ 2021
All news about DICERNA PHARMACEUTICALS, INC.
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..
CI
2021Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
2021DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..
PU
2021DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2021Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
2021Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Bob D. Brown President
Shreeram Aradhye Chief Medical Officer & Executive Vice President
James B. Weissman Chief Operating Officer & Executive Vice President
Jamie Haney Director
Ulrich Christian Otte Director
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.0.00%2 986
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612